VaLogic Bio’s Post

Eli Lilly is setting a new standard in biotech partnerships with its Gateway Labs initiative, which fosters collaboration by offering co-working spaces and access to Lilly’s vast resources. As they announce expansions in Boston and San Diego, it's clear Lilly is leveraging the success of its weight loss drugs, Mounjaro and Zepbound, to further enhance these partnerships. This move raises several questions for the industry: ▪️ How will Lilly's collaborative model influence Big Pharma’s approach to innovation? ▪️ What long-term benefits might this hold for the biotech sector? ▪️ How can emerging biotechs maximize such opportunities? Let's discuss how strategic partnerships like these could shape the future of healthcare. What are your thoughts? #Biotechnology #PharmaceuticalIndustry #HealthcareInnovation #StrategicPartnerships #EliLilly

➡ From Big Pharma to Biotech? Being a CEO of a small biotech differs from being one of the CEOs of a big pharma. In biotech, convincing investors of a project's worth is crucial for funding, while in pharma, if a project has merit, it’s likely to be funded. The main difference between big pharma and biotech is biotech's fast-moving and dynamic nature, which has resulted in a difference in the CEO role.💼 Three Key Insights into the Biotech CEO 👇 1️⃣ Connection - a personal connection to the molecule you work with. 2️⃣ Determination - a strong desire to make your molecules work despite limited funding. 3️⃣ Freedom - to make decisions in real-time when necessary. #ZijlstraConsultancy #CDMO #Marketing #Biotech

🚀 Breaking Barriers in Pharma Launches! 🚀 One of the biggest challenges pharma companies face when launching (or relaunching) a drug is speed to market. Missed timelines, incomplete tasks, and the complexity of managing countless pre-launch and post-launch activities can throw even the most strategic plans off course. This issue affects every player in the industry—from emerging Biopharma to large, established companies. 💡 That’s why we built MAH. MAH is designed specifically to address these launch delays, bringing precision and simplicity to a notoriously complex process. Imagine a launch where every activity, from early prep to post-launch tracking, is seamlessly managed on a single platform. 👉 Faster, smarter, and more efficient commercialization is here. Are you ready to transform your launch strategy? #PharmaLaunch #SpeedToMarket #LifeSciences #Innovation #PharmaTransformation

Pls like the post below and take part in our survey about Pharma launches.

⚠️ The Time Sinkhole: Development Delays That Drain Momentum ⚠️ Time is the lifeblood of #biotherapeutics development – Yet, losing time on process development or redesigning of inefficient processes is all too common and can drain your team’s momentum fast. 💡bespark*bio’s Solution: Jumpstart with Pre-developed Frameworks We utilize modular process building blocks, meticulously pre-developed and optimized. These building blocks seamlessly integrate into comprehensive process streams providing #frameworks for swift and flexible process adaptation. By leveraging this prior #knowledge, we replace time-consuming trial-and-error development with informed decisions, significantly accelerating your project’s timeline while minimizing the risk of experimental setbacks. 🚀 The Result: Streamline Success By streamlining complexity and reducing workload, we free your team to focus on breakthroughs, not bottleneck - turning your development pace into a competitive #advantage. #Biotech, #Pharma, #LifeSciences, #ProcessDevelopment, #Innovation,#ViralVectors, #GeneTherapy, #GeneAndCellTherapy

BRAVE LAUNCH CHALLENGES ONLY THE BRAVE is a strategic consultancy specialising in supporting Pharma companies with launching innovative new treatments. We are seeing considerable change in the industry - new technology and innovation, new environmental challenges and organisational changes to address these. We are looking to compile an industry wide view of the changing nature of the challenges faced by teams preparing launches and we would like your input, particularly if you are in a medical or commercial role. So, if you would like to take part in the survey and have your voice heard and work in a medical or commercial role preparing a launch, whether early or late stage, please like this post with a 👍 and we will share the link with you directly. As a participant, we will share the results with you so that you too have a broader perspective on the challenges faced across the industry. If you are facing challenges in preparing a launch, please do also reach out to us for a discussion. You can shoot an email to hello@onlythebrave.uk #BRAVEteam #BRAVElaunch #medcomms #pharma #biotech

Fleming CFO supports early-stage life sciences companies to build an organized financial framework throughout all stages of clinical discovery and development. Explore our services to see how a fractional CFO can streamline your finances: https://lnkd.in/gaaxgwbJ #lifesciences | #biotech | #pharma | #medtech | #startup

🚀 Catalysts for Accelerated Innovation: Strategic Partnerships in Biotech 🚀 In the dynamic world of biotechnology, strategic partnerships are not just beneficial; they’re essential. From licensing agreements to equity investments, these collaborations enable biotech start-ups to overcome resource constraints and the complex, costly nature of drug development. With major pharma companies like Novartis AG expecting up to 40% of their pipeline from biotech, the reliance on these partnerships has never been more critical. Biotech start-ups, driven by the quest to revolutionize healthcare, often face significant hurdles. Strategic partnerships with larger pharma companies, academic institutions, or research organizations can offer more than financial support—they bring shared vision, expertise, and resources to the table. This article by Joab Williamson and Alexander Spicer delves into the transformative potential of these partnerships. Learn how they serve as a driving force for innovation, helping biotech companies navigate the high-stakes landscape of drug development. 🔗Read the full article here: https://lnkd.in/gHyxnt-3 #Biotech #Pharma #Innovation #StrategicPartnerships #Healthcare #DrugDevelopment #R&D #Novartis #Biotechnology #Startups #MedicalScience #Collaboration #LifeSciences #ClinicalOperations #CorporateDevelopment

ARTICLE – The future of #pharma is being reshaped through collaboration and cutting-edge technology. Experts from Bristol Myers Squibb, Emerson's Automation Technologies & Solutions and FUJIFILM Diosynth Biotechnologies share the role that each of the companies play in shortening the time it takes to get drugs to market faster. The impact of trust and technology, changes in manufacturing to accelerate time to market, and automation at the core are a few topics discussed in this article. Read the full article in Pharma Manufacturing https://ow.ly/tGPU30sGjuG #software #analytics

ARTICLE – The future of #pharma is being reshaped through collaboration and cutting-edge technology. Experts from Bristol Myers Squibb, Emerson's Automation Technologies & Solutions and FUJIFILM Diosynth Biotechnologies share the role that each of the companies play in shortening the time it takes to get drugs to market faster. The impact of trust and technology, changes in manufacturing to accelerate time to market, and automation at the core are a few topics discussed in this article. Read the full article in Pharma Manufacturing https://ow.ly/nGSw30sGp8L #software #analytics